Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways

International Immunopharmacology

Volumn 25, Issue 1, 2015, Pages 49-54

  Zhou, Chi ^a   Liu, Wengang ^b   He, Wei ^a   Wang, Haibin ^a   Chen, Qunqun ^a   Song, Houpan ^c  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^c HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

MAPK; NF B; Osteoclast; RANKL; Saikosaponin a

Indexed keywords

CATHEPSIN K; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NFATC1 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PROTEIN C FOS; SAIKOSAPONIN A; STRESS ACTIVATED PROTEIN KINASE; TRACP PROTEIN; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE P38; OLEANOLIC ACID; SAIKOSAPONIN; SAPONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BONE MARROW CELL; BUPLEURUM; CELL DIFFERENTIATION; CELL LINE; CHINESE MEDICINE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MONOCYTE; PHYSIOLOGY;

ANIMALS; BONE MARROW CELLS; BUPLEURUM; CELL DIFFERENTIATION; CELL LINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEDICINE, CHINESE TRADITIONAL; MICE; MONOCYTES; NF-KAPPA B; OLEANOLIC ACID; OSTEOCLASTS; OSTEOPOROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND; SAPONINS; SIGNAL TRANSDUCTION;

EID: 84921647351     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.01.010     Document Type: Article

References (33)

1. NIH Consensus development panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy JAMA 285 2001
2. R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, and A. Tosteson Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 2007 465 475
3. M. Varenna, F. Bertoldo, M. Di Monaco, A. Giusti, G. Martini, and M. Rossini Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature Reumatismo 65 2013 143 166
4. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
5. N. Udagawa, N. Takahashi, T. Akatsu, H. Tanaka, T. Sasaki, and T. Nishihara Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells Proc Natl Acad Sci U S A 87 1990 7260 7264
6. G.-Q. Yao, Sun B-h, E.E. Hammond, E.N. Spencer, M.C. Horowitz, and K.L. Insogna The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells J Biol Chem 273 1998 4119 4128
7. B.G. Darnay, V. Haridas, J. Ni, P.A. Moore, and B.B. Aggarwal Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase J Biol Chem 273 1998 20551 20555
8. S.Y. Lee, A. Reichlin, A. Santana, K.A. Sokol, M.C. Nussenzweig, and Y. Choi TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival Immunity 7 1997 703 713
9. G.R. Mundy Osteoporosis and inflammation Nutr Rev 65 2007 S147 S151
10. J. Lam, S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross, and S.L. Teitelbaum TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand J Clin Invest 106 2000 1481 1488
11. Y.-H. Zhang, A. Heulsmann, M.M. Tondravi, A. Mukherjee, and Y. Abu-Amer Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways J Biol Chem 276 2001 563 568
12. J.-W. Lee, A. Iwahashi, S.-i. Hasegawa, T. Yonezawa, W.B. Jeon, and B.-Y. Cha Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells J Nat Med 66 2012 8 16
13. B. Sung, S.G. Cho, M. Liu, and B.B. Aggarwal Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling Int J Cancer 129 2011 2062 2072
14. C.-H. Tang, C.-S. Chang, T.-W. Tan, S.-C. Liu, and J.-F. Liu The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation Eur J Pharmacol 648 2010 59 66
15. H.-M. Chang, P.P. But, S.-C. Yao, L. Wang, and S. Yeung Pharmacology and applications of Chinese materia medica Book Rev 1 2000 174 177
16. Y. Sun, T.-T. Cai, X.-B. Zhou, and Q. Xu Saikosaponin a inhibits the proliferation and activation of T cells through cell cycle arrest and induction of apoptosis Int Immunopharmacol 9 2009 978 983
17. P.W. Cheng, L.T. Ng, L.C. Chiang, and C.C. Lin Antiviral effects of saikosaponins on human coronavirus 229E in vitro Clin Exp Pharmacol Physiol 33 2006 612 616
18. C.-N. Lu, Z.-G. Yuan, X.-L. Zhang, R. Yan, Y.-Q. Zhao, and M. Liao Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-κB signaling pathway Int Immunopharmacol 14 2012 121 126
19. K.T. Steeve, P. Marc, T. Sandrine, H. Dominique, and F. Yannick IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology Cytokine Growth Factor Rev 15 2004 49 60
20. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, and T.J. Martin Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr Rev 20 1999 345 357
21. M. Asagiri, and H. Takayanagi The molecular understanding of osteoclast differentiation Bone 40 2007 251 264
22. T. Nakashima, and H. Takayanagi New regulation mechanisms of osteoclast differentiation Ann N Y Acad Sci 1240 2011 E13 E18
23. G. Franzoso, L. Carlson, L. Xing, L. Poljak, E.W. Shores, and K.D. Brown Requirement for NF-κB in osteoclast and B-cell development Gene Dev 11 1997 3482 3496
24. Z.H. Lee, and H.-H. Kim Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts Biochem Biophys Res Commun 305 2003 211 214
25. C. Wang, J.H. Steer, D.A. Joyce, K.H. Yip, M.H. Zheng, and J. XU 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-κB activation J Bone Miner Res 18 2003 2159 2168
26. K.H.M. Yip, M.H. Zheng, H.T. Feng, J.H. Steer, D.A. Joyce, and J. Xu Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-κB activity J Bone Miner Res 19 2004 1905 1916
27. M.L. Chaisson, D.G. Branstetter, J.M. Derry, A.P. Armstrong, M.E. Tometsko, and K. Takeda Osteoclast differentiation is impaired in the absence of inhibitor of κB kinase α J Biol Chem 279 2004 54841 54848
28. M.G. Ruocco, S. Maeda, J.M. Park, T. Lawrence, L.-C. Hsu, and Y. Cao IκB kinase (IKK) β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss J Exp Med 201 2005 1677 1687
29. J. Zhu, C. Luo, P. Wang, Q. He, J. Zhou, and H. Peng Saikosaponin A mediates the inflammatory response by inhibiting the MAPK and NF-κB pathways in LPS-stimulated RAW 264.7 cells Exp Ther Med 5 2013 1345 1350
30. T. Miyazaki, H. Katagiri, Y. Kanegae, H. Takayanagi, Y. Sawada, and A. Yamamoto Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts J Cell Biol 148 2000 333 342
31. H. Hotokezaka, E. Sakai, K. Kanaoka, K.-i. Saito, K.- Matsuo, and H. Kitaura U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264. 7 cells into osteoclast-like cells J Biol Chem 277 2002 47366 47372
32. N. Kobayashi, Y. Kadono, A. Naito, K. Matsumoto, T. Yamamoto, and S. Tanaka Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis EMBO J 20 2001 1271 1280
33. A.E. Grigoriadis, Z.-Q. Wang, M.G. Cecchini, W. Hofstetter, R. Felix, and H.A. Fleisch C-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling Science 266 1994 443 448